Mankind Pharma Faces Mixed Market Sentiment Amid Valuation Adjustments
Mankind Pharma has recently adjusted its evaluation score, reflecting changes in technical indicators and valuation metrics. The mixed technical signals suggest varying market sentiment, while the company's valuation metrics indicate a premium status compared to industry peers, highlighting the complexities of its financial position.
Mankind Pharma, a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects notable shifts in both technical and valuation metrics. The technical indicators suggest a transition in market sentiment, with the MACD signaling bearish conditions on a weekly basis. The moving averages also indicate a bearish trend, while the KST shows a mildly bullish stance. This mixed technical landscape may influence perceptions of the stock's momentum.
On the valuation front, Mankind Pharma's metrics indicate a shift from an expensive to a very expensive classification. The price-to-earnings ratio stands at 49.48, and the price-to-book value is recorded at 9.32. These figures suggest that the stock is trading at a premium compared to its industry peers. Additionally, the company's return on equity (ROE) is at 20.02%, which, while indicative of management efficiency, also contributes to the elevated valuation.
Overall, the adjustment in Mankind Pharma's evaluation score highlights the complexities of its current market position and financial metrics, reflecting both technical trends and valuation considerations.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
